MedTrace Logo

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

NCT02238483 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2018-05-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether AZD7624 can reduce acute Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients on COPD maintenance therapy with a history of frequent acute exacerbations.

Conditions

  • Chronic Obstructive Pulmonary Disease COPD

Interventions

DRUG

AZD7624 1.0 mg

Inhaled AZD7624 solution, 11 mg/mL

DRUG

Placebo

Inhaled placebo solution

Sponsors & Collaborators

Principal Investigators

  • Naimish Patel, MD, PhD · AstraZeneca R&D Boston

  • Barry Make, MD, FCCP, FACVPR · National Jewish Health, Denver, United States

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-28
Primary Completion
2016-04-04
Completion
2016-04-04
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Chile
  • Netherlands
  • Peru
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02238483 on ClinicalTrials.gov